Airna

Kerna

This company develops an artificial intelligence platform to design and deliver messenger ribonucleic acid medicines for patients with previously untreatable conditions.

Immitra Bio

This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.

Noara Therapeutics

This company engineers stable and immunosilent ribonucleic acid therapies using machine intelligence to treat patients with chronic and complex diseases.

Alia Therapeutics

The company develops gene editing medicines for patients with genetic diseases.

ADARx Pharmaceuticals

This clinical-stage biotechnology company develops RNA-targeting therapeutics for patients with genetic, cardiometabolic, complement-mediated, and central nervous system diseases.

Cardior

This company develops RNA-based therapeutics designed to prevent, repair and reverse heart diseases for patients with cardiac dysfunctions.

Shape Therapeutics

The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.

Serna Bio

This company develops an AI-native platform to discover small molecule drugs targeting RNA for pharmaceutical partners treating respiratory and other complex diseases.